ClinicalTrials.gg
BiologicalDrug

Nivolumab and Recombinant Human Hyaluronidase clinical trials

Also written BMS-986298.

A product of Nivolumab; its studies count on that page too.

studies test it
3
open now
0
in phase 3
2
first study started
2021

How each study uses Nivolumab and Recombinant Human Hyaluronidase has had a first review. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
27 Dec 2024 · OPDIVO QVANTIG · BLA 761381 (FDA, Drugs@FDA)
European Union
19 Jun 2015 · Opdivo · EMEA/H/C/003985 (EMA; as Nivolumab)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Nivolumab/rHuPH20
2

Development codes

BMS-986298
3

Studies by the year they started

3 studies that test it; most in 2021 (1)

Studies that test Nivolumab and Recombinant Human Hyaluronidase, by start year
YearStudies
20211
20221
20231

By phase

A phase 1/2 study counts in both.

Phase 2
1
Phase 3
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 3 · Other 0

Bristol-Myers Squibb (3)

Related medicines

As reviewed, each with the page that says it.

Studies

Open first, then newest update. How each study uses Nivolumab and Recombinant Human Hyaluronidase has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 3

Behind its US label · 24 — the studies the FDA label of OPDIVO QVANTIG describes

From the Clinical Studies section of OPDIVO QVANTIG (2026-05), as openFDA has it. A study the site does not hold is left out.

Tested with established drugs · 2 — they are given beside it
Tested in a combination · 1 — another drug in the study is under test too
Given beside what is tested · 1 — usual care or a partner of the new treatment
Start the discussion